Mizuho raises Amylyx stock price target to $30 on higher pricing

Mizuho, a prominent investment firm, has uplifted its price target on Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) shares to $30, up from the previous $24 valuation. The firm has retained an Outperform rating, attributing the increase to the company's strong financial position and positive outlook on its lead asset, avexitide. This drug is a novel GLP-1 receptor antagonist designed to treat post-bariatric hypoglycemia, a rare condition.

Mizuho's updated pricing assumptions for avexitide led to the revised target, which suggests a potential 39% upside from the current share price. The company estimates a possible $10 to $15 gain on the stock if Phase 3 LUCIDITY study results are favorable, expected by late August or early September. Mizuho highlighted that Amylyx's stock has surged 79% year-to-date, outperforming the XBI index by 29%.

The firm's financial assessment reveals that Amylyx has more cash than debt on its balance sheet and liquid assets surpassing short-term obligations by a significant margin. Despite a larger-than-expected second-quarter loss, Amylyx continues to progress towards crucial Phase 3 data for avexitide, keeping investors closely watching its cash reserves and late-stage pipeline advancements.